Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset.
Research aimed at developing new therapies for Parkinson's disease (PD) critically depend on valid animal models of the disease that allows for repeated testing of motor disabilities over extended time periods. We here present an extensive characterization of a wide range of motor symptoms in the 6-OHDA marmoset model of PD when tested over several months. The severity of motor deficits was quantified in two ways: (i) through manual scoring protocols appropriately adapted to include species specific motor behavior and (ii) using automated quantitative motion tracking based on image processing of the digital video recordings. We show that the automated methods allow for rapid and reliable characterization of motor dysfunctions, thus complementing the manual scoring procedures, and that robust motor symptoms lasting for several months could be induced when using a two-stage neurotoxic lesioning procedure involving one hemisphere at a time. This non-human primate model of PD should therefore be well suited for long-term evaluation of novel therapies for treatment of PD.
Edmond and Lily Safra International Institute of Neuroscience, Santos Dumont Institute, Macaíba/RN 59280-000, Brazil; Psychobiology Program, Federal Univ. of Rio Grande do Norte, Natal, 59078-970, Brazil; Bacharelado em Ciências Biológicas, Instituto de Ciências e Tecnologia das Águas, Universidade Federal do Oeste do Pará (UFOPA), Santarém, Pará, Brazil.
M
M
Santana
Integrative Neurophysiology and Neurotechnology, Neuronano Research Center, Department of Experimental Medical Sciences, Lund University, Medicon Village, Building 404 A2 Scheelevägen 8, 223 81 Lund, Sweden; Mathematics LTH Centre for Mathematical Sciences, Faculty of Engineering, Lund University, S-22184 Lund, Sweden.
T
T
Palmér
Edmond and Lily Safra International Institute of Neuroscience, Santos Dumont Institute, Macaíba/RN 59280-000, Brazil; State Univ. of Rio Grande do Norte, Mossoró/RN, 59610-210, Brazil.
H
H
Simplício
Edmond and Lily Safra International Institute of Neuroscience, Santos Dumont Institute, Macaíba/RN 59280-000, Brazil; Programa de Fisiologa y Biofísica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Independencia 1027, Santiago 8389100, Chile.
R
R
Fuentes
Integrative Neurophysiology and Neurotechnology, Neuronano Research Center, Department of Experimental Medical Sciences, Lund University, Medicon Village, Building 404 A2 Scheelevägen 8, 223 81 Lund, Sweden. Electronic address: Per.Petersson@med.lu.se.
P
P
Petersson
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002144:Callithrix; D004195:Disease Models, Animal; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D016627:Oxidopamine / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D012720:Severity of Illness Index
D016627:Oxidopamine
Animal model; Motor behavior; Parkinson's disease